Loading
The most advanced metabolic therapy available, acting on both GIP and GLP-1 hormone receptors. This synergistic effect leads to superior appetite control, enhanced fat burning, and significant improvements in cardiovascular risk factors compared to single-receptor agonists.
Clinical data suggests dual-agonists achieve greater average fat reduction and metabolic optimization than GLP-1 alone.
Specifically targets and reduces stubborn visceral fat around the organs, improving overall metabolic health.
Dual receptor action provides a more complete reset of insulin sensitivity, ideal for those with severe resistance.
Low initiation dose begins mapping the GIP and GLP-1 receptors. Early signs include reduced hunger and slight energy stabilization.
As dosage scales, the synergistic effect of GIP/GLP-1 becomes apparent. Substantial decreases in portion sizes and cravings occur.
Optimal therapeutic levels are reached. Body composition changes markedly as fat stores are utilized for energy.
Your prescription is compounded at an FDA-registered 503A pharmacy and overseen by an independent licensed physician. We ensure the highest standard of safety and care.